Sugi Predict

Sugi Predict / Compounds / SCHEMBL11717

SCHEMBL11717

SCHEMBL11717

CCC(=O)N1CCC(N)CC1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GNAI3 P08754 1/20 0.61
▸ GNAO1 P09471 1/20 0.61
▸ GNAI1 P63096 1/20 0.61
▸ EPHX2 P34913 9/20 0.51
▸ ALDH1A1 P00352 2/20 0.45
▸ CHRNB2 P17787 2/20 0.44
▸ CHRNA3 P32297 2/20 0.44
▸ CHRNA4 P43681 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ CHRNB3 Q05901 1/20 0.44
▸ CHRNA6 Q15825 1/20 0.44
▸ CACNA1B Q00975 2/20 0.43
▸ EPHX1 P07099 1/20 0.43
▸ CHRNB4 P30926 1/20 0.42
▸ CHRNA7 P36544 1/20 0.42
▸ BLM P54132 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5744811 0.88 GNAI3 (0.49) GNAI3GNAO1GNAI1EPHX2ALDH1A1
SCHEMBL15731364 0.88 GNAI3 (0.49) GNAI3GNAO1GNAI1EPHX2ALDH1A1
SCHEMBL3403317 0.88 GNAI3 (0.49) GNAI3GNAO1GNAI1EPHX2ALDH1A1
SCHEMBL14996187 0.84 EPHX2 (0.53) GNAI3GNAO1GNAI1EPHX2ALDH1A1
SCHEMBL1562717 0.83 GNAI3 (0.72) GNAI3GNAO1GNAI1EPHX2ALDH1A1
SCHEMBL9224930 0.80 GNAI3 (0.84) GNAI3GNAO1GNAI1NPC1CACNA1B
SCHEMBL2439450 0.80 GNAI3 (0.53) GNAI3GNAO1GNAI1ALDH1A1NPC1
SCHEMBL10282539 0.80 ALDH1A1 (0.67) EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4
SCHEMBL7487836 0.80 EPHX2 (0.53) EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4
SCHEMBL3968814 0.80 GNAI3 (0.53) GNAI3GNAO1GNAI1ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445501-B2 Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines TAKEDA GMBH (DE) 2013-05-21 — — US claimed
EP-2247594-A1 PYRROLOPYRIMIDINECARBOXAMIDES Nycomed GmbH (DE) 2010-11-10 — — EP claimed
WO-2009106531-A1 PYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2009-09-03 — — WO claimed
US-12486222-B2 Compounds as soluble epoxide hydrolase inhibitors UNIVERSITAT DE BARCELONA (ES) 2025-12-02 — — US disclosed
US-20250115548-A1 COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS UNIV BARCELONA (ES) 2025-04-10 — — US disclosed
US-20240400575-A1 POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS UNIV BARCELONA (ES) 2024-12-05 — — US disclosed
US-20240293362-A1 Soluble Epoxide Hydrolase Inhibitors and Use Thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2024-09-05 — — US disclosed
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-25 — — US disclosed
CN-118206529-A Dihydrobenzimidazolone C4医药公司 2024-06-18 — — CN disclosed
US-20240182406-A1 COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS UNIVERSITAT DE BARCELONA (ES) 2024-06-06 — — US disclosed
CN-118019728-A Compounds as soluble epoxide hydrolase inhibitors 巴塞罗那大学 2024-05-10 — — CN disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 — — WO disclosed
WO-2009121063-A2 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS (US) 2009-10-01 — — WO disclosed
WO-2009106531-A1 PYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2009-09-03 — — WO disclosed
EP-1343503-B1 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORP (US) 2008-11-12 — — EP disclosed
CN-101291582-A Novel imidazo based heterocycles ABBOTT LAB (US) 2008-10-22 — — CN disclosed
US-20080175914-A1 Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED 2008-07-24 — — US disclosed
US-20080175914-A1 Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED 2008-07-24 — — US disclosed
US-7332509-B2 Heterocyclic amides, a process for their preparation, compositions comprising them and their use MERIAL LIMITED (US) 2008-02-19 — — US disclosed
WO-2004024728-A2 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182406-A1 COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, LTA4H GNAI3 2006/4885GNAO1 1404/4885GNAI1 1714/4885
US-20250115548-A1 COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, LTA4H GNAI3 2006/4885GNAO1 1404/4885GNAI1 1714/4885
US-20080175914-A1 Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors PDE5A, PDE3B, PDE4A GNAI3 603/4885GNAO1 134/4885GNAI1 539/4885
US-12486222-B2 Compounds as soluble epoxide hydrolase inhibitors EPHX1, EPHX2, LTA4H GNAI3 2006/4885GNAO1 1404/4885GNAI1 1714/4885
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME HAVCR2, HDGF, HCCS GNAI3 835/4885GNAO1 764/4885GNAI1 618/4885
US-20240293362-A1 Soluble Epoxide Hydrolase Inhibitors and Use Thereof EPHX1, EPHX2, NCEH1 GNAI3 2110/4885GNAO1 1868/4885GNAI1 2295/4885
US-20240400575-A1 POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 GNAI3 2785/4885GNAO1 1209/4885GNAI1 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.